Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

IGC Pharma

Tracked across 2 events · 12 articles · First seen Apr 28, 2026 · Last active Aug 17, 2026

Sentiment
15
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 20
Business
Impact: IGC Pharma announced its participation in a caregiver-focused podcast to raise awareness for Alzheimer's disease agitation and support patient engagement in its Phase 2 CALMA clinical trial, which is nearing completion of enrollment. This outreach aims to accelerate the trial's progress and potential future drug development.
Apr 28, 2026 · 6 articles
2 10
Business
IGC Pharma, Inc. reported financial results for Q2 2026 and provided an update on its lead Alzheimer's program, IGC-AD1. The Phase 2 CALMA trial reached its 146-patient baseline randomization target and is within six randomizations…
Impact: IGC Pharma is the central entity, reporting Q2 results and advancing its lead Alzheimer's candidate. The trial progress and equity conversion are positive, but financial losses and low cash remain concerns.
Aug 17, 2026 · 6 articles
90 IGC Pharma advanced enrollmentIGC Pharma Q2 2026 CALMA...
40 IGC Pharma received psilocybin authorization ColombiaIGC Pharma Q2 2026 CALMA...
30 IGC Pharma reported Q2 resultsIGC Pharma Q2 2026 CALMA...
ERGEN INTELLIGENCE
Track IGC Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.